ArticleMathematical biosciences2021
Immunity after COVID-19: Protection or sensitization?
Article in Mathematical biosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- SARS-CoV-2 pathophysiology and post-vaccination severity: a systematic review.Immunologic research · 2024Pooled it
- Study on the virulence evolution of SARS-CoV-2 and the trend of the epidemics of COVID-19.Mathematical methods in the applied sciences · 2022Article
- Comparing the dynamics of COVID-19 infection and mortality in the United States, India, and Brazil.Physica D. Nonlinear phenomena · 2022Article
- Estimating a continuously varying offset between multivariate time series with application to COVID-19 in the United States.The European physical journal. Special topics · 2022Article
- Trends in COVID-19 prevalence and mortality: A year in review.Physica D. Nonlinear phenomena · 2021Article
- The Incidence and Severity of Post-Vaccination Reactions after Vaccination against COVID-19.Vaccines · 2021Article
- Incidence and severity of SARS-CoV-2 virus post COVID-19 vaccination: A cross-sectional study in India.Clinical epidemiology and global healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motivated by historical and present clinical observations, we discuss the possible unfavorable evolution of the immunity (similar to documented antibody-dependent enhancement scenarios) after a first infection with COVID-19. More precisely we ask the question of how the epidemic outcomes are affected if the initial infection does not provide immunity but rather sensitization to future challenges. We first provide background comparison with the 2003 SARS epidemic. Then we use a compartmental epidemic model structured by immunity level that we fit to available data; using several scenarios of the fragilization dynamics, we derive quantitative insights into the additional expected numbers of severe cases and deaths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.